As the speed and scale of AI-generated code continue to skyrocket within organizations in every industry, "Active Coverage" has become imperative, according to the company, which has been AI-native ...

TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...

As this report about automation in quality assurance states, ensuring optimal test coverage is among the most arduous tasks in QA. This is because the calculation of this metric depends on a plethora ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...

Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...

It's the first and one of the hardest tests of the Democrats' ambitious plan to overhaul the nation's health care system: establishing a federally funded program in the next 90 days to cover people ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare ...